Xiao, NianzhouStarr, MichelleStolfi, AdrienneHamdani, GiladHashmat, ShireenKiessling, Stefan G.Sethna, ChristinaKallash, MahmoudMatloff, RobynWoroniecki, RobertSanderson, KeiaYamaguchi, IkuyoCha, Stephen D.Semanik, Michael G.Chanchlani, RahulFlynn, Joseph T.Mitsnefes, Mark2024-06-242024-06-242024Xiao N, Starr M, Stolfi A, et al. Blood Pressure Outcomes in NICU-Admitted Infants with Neonatal Hypertension: A Pediatric Nephrology Research Consortium Study. J Pediatr. 2024;264:113765. doi:10.1016/j.jpeds.2023.113765https://hdl.handle.net/1805/41820Objective: To describe the blood pressure outcomes of infants admitted to the neonatal intensive care unit (NICU) with idiopathic (nonsecondary) hypertension (HTN) who were discharged on antihypertensive therapy. Study design: Retrospective, multicenter study of 14 centers within the Pediatric Nephrology Research Consortium. We included all infants with a diagnosis of idiopathic HTN discharged from the NICU on antihypertensive treatment. The primary outcome was time to discontinuation of antihypertensive therapy, grouped into (≤6 months, >6 months to 1 year, and >1 year). Comparisons between groups were made with χ2 tests, Fisher's exact tests, and ANOVA. Results: Data from 118 infants (66% male) were included. Calcium channel blockers were the most prescribed class of antihypertensives (56%) in the cohort. The percentages remaining on antihypertensives after NICU discharge were 60% at 6 months, 26% at 1 year, and 7% at 2 years. Antenatal steroid treatment was associated with decreased likelihood of antihypertensive therapy >1 year after discharge. Conclusions: This multicenter study reports that most infants admitted to the NICU diagnosed with idiopathic HTN will discontinue antihypertensive treatment by 2 years after NICU discharge. These data provide important insights into the outcome of neonatal HTN, but should be confirmed prospectively.en-USPublisher PolicyNICUHypertensionNeonatesPediatricArticle